Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

Solid Biosciences Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

- DUCHENNE (SGT-003): 15 PARTICIPANTS DOSED IN THE PHASE 1/2 INSPIRE DUCHENNE TRIAL AND DOSING REMAINS ONGOING; ON TRACK TO DISCUSS REGULATORY PATHWAYS WITH U.S. FDA IN Q4 2025 -

SOLID BIOSCIENCES REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES

CHARLESTOWN, MASS., AUG. 01, 2025 (GLOBE NEWSWIRE) -- SOLID BIOSCIENCES INC.(NASDAQ: SLDB) (THE COMPANY), A LIFE SCIENCES COMPANY DEVELOPING PRECISION GENETIC MEDICINES FOR NEUROMUSCULAR AND CARDIAC DISEASES, TODAY ANNOUNCED GRANTS OF 55,450 RESTRICTED STOCK UNITS (RSUS) TO FOUR NEWLY HIRED EMPLOYEES.

SOLID BIOSCIENCES REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

- SGT-501 HAS NOW RECEIVED FDA FAST TRACK, ORPHAN DRUG AND RARE PEDIATRIC DISEASE DESIGNATIONS - - POTENTIAL FIRST-IN-CLASS THERAPY WITH FDA IND CLEARANCE AND HEALTH CANADA CTA APPROVAL DESIGNED TO ADDRESS UNDERLYING CAUSES OF CPVT, A LIFE-THREATENING, ARRHYTHMOGENIC CARDIAC CONDITION - - SOLID EXPECTS TO INITIATE PHASE 1B CLINICAL TRIAL OF SGT-501 IN THE FOURTH QUARTER OF 2025 - CHARLESTOWN, MASS., JULY 23, 2025 (GLOBE NEWSWIRE) -- SOLID BIOSCIENCES INC. (NASDAQ: SLDB), A CLINICAL STAGE LIFE SCIENCES COMPANY DEVELOPING PRECISION GENETIC MEDICINES FOR NEUROMUSCULAR AND CARDIAC DISEASES, TODAY ANNOUNCED THAT IT RECEIVED FAST TRACK DESIGNATION FROM THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) FOR SGT-501, THE COMPANY'S NOVEL, AAV-BASED INVESTIGATIONAL GENE THERAPY FOR THE TREATMENT OF CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA (CPVT).

SOLID BIOSCIENCES RECEIVES FDA FAST TRACK DESIGNATION FOR SGT-501 FIRST-IN-CLASS GENE THERAPY FOR CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA (CPVT)

- SGT-501 IS A NOVEL GENE THERAPY FOR RARE, LIFE-THREATENING, GENETIC ARRHYTHMOGENIC DISEASE WITH NO APPROVED THERAPIES - - SGT-501 HAS RECEIVED ORPHAN DRUG DESIGNATION AND RARE PEDIATRIC DISEASE DESIGNATION FROM THE FDA - - SOLID EXPECTS TO INITIATE PHASE 1B CLINICAL TRIAL OF SGT-501 IN THE FOURTH QUARTER OF 2025 - - EXPANDS SOLID'S CLINICAL PIPELINE TO INCLUDE FIRST CARDIAC INDICATION WITH URGENT UNMET MEDICAL NEED - CHARLESTOWN, MASS., JULY 08, 2025 (GLOBE NEWSWIRE) -- SOLID BIOSCIENCES INC. (NASDAQ: SLDB) (THE COMPANY OR SOLID), A LIFE SCIENCES COMPANY DEVELOPING PRECISION GENETIC MEDICINES FOR NEUROMUSCULAR AND CARDIAC DISEASES, TODAY ANNOUNCED APPROVAL OF ITS INVESTIGATIONAL NEW DRUG (IND) APPLICATION BY THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) AND CLINICAL TRIAL APPLICATION (CTA) BY HEALTH CANADA FOR SGT-501, A NOVEL GENE THERAPY APPROACH FOR THE TREATMENT OF CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA (CPVT), A HIGHLY MALIGNANT, ARRHYTHMOGENIC CHANNELOPATHY CAUSED BY GENETIC MUTATIONS THAT IMPACT THE RYANODINE RECEPTOR (RYR2) IN CARDIAC MUSCLE.

SOLID BIOSCIENCES ANNOUNCES FDA IND AND HEALTH CANADA CTA APPROVAL FOR FIRST-IN-CLASS CARDIAC GENE THERAPY TO TREAT CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA (CPVT)

CHARLESTOWN, MASS., JULY 01, 2025 (GLOBE NEWSWIRE) -- SOLID BIOSCIENCES INC.(NASDAQ: SLDB) (THE COMPANY), A LIFE SCIENCES COMPANY DEVELOPING PRECISION GENETIC MEDICINES FOR NEUROMUSCULAR AND CARDIAC DISEASES, TODAY ANNOUNCED GRANTS OF 105,330 RESTRICTED STOCK UNITS (RSUS) TO SEVEN NEWLY HIRED EMPLOYEES.

CHARLESTOWN, MASS., JUNE 03, 2025 (GLOBE NEWSWIRE) -- SOLID BIOSCIENCES INC.(NASDAQ: SLDB) (THE COMPANY), A LIFE SCIENCES COMPANY DEVELOPING PRECISION GENETIC MEDICINES FOR NEUROMUSCULAR AND CARDIAC DISEASES, TODAY ANNOUNCED GRANTS OF 34,550 RESTRICTED STOCK UNITS (RSUS) TO TWO NEWLY HIRED EMPLOYEES.

CHARLESTOWN, MASS., MAY 28, 2025 (GLOBE NEWSWIRE) -- SOLID BIOSCIENCES INC. (NASDAQ: SLDB) (THE COMPANY OR SOLID), A LIFE SCIENCES COMPANY DEVELOPING PRECISION GENETIC MEDICINES FOR NEUROMUSCULAR AND CARDIAC DISEASES, ANNOUNCED THAT BO CUMBO, PRESIDENT AND CEO, AND GABRIEL BROOKS, M.D.

SOLID BIOSCIENCES TO PARTICIPATE AT THE JEFFERIES GLOBAL HEALTHCARE CONFERENCE

- DUCHENNE (SGT-003) : PARTICIPANT DOSING ONGOING IN THE PHASE 1/2 INSPIRE DUCHENNE TRIAL; SOLID ON TRACK TO DISCUSS ACCELERATED PATHWAYS WITH U.S. FDA LATER IN 2025 - - FA (SGT-212): DOSING OF FIRST PARTICIPANT ANTICIPATED IN THE SECOND HALF OF 2025 - - CPVT (SGT-501): FDA IND ON TRACK FOR SUBMISSION FIRST HALF OF 2025 - - CASH: COMPANY ENDED FIRST QUARTER 2025 WITH $306.9 MILLION IN CASH, CASH EQUIVALENTS, INVESTMENTS AND AVAILABLE-FOR-SALE SECURITIES; SOLID HAS ANTICIPATED CASH RUNWAY INTO THE FIRST HALF OF 2027 - CHARLESTOWN, MASS., MAY 15, 2025 (GLOBE NEWSWIRE) -- SOLID BIOSCIENCES INC. (NASDAQ: SLDB) (THE COMPANY OR SOLID), A LIFE SCIENCES COMPANY DEVELOPING PRECISION, NEXT GENERATION, GENETIC MEDICINES FOR NEUROMUSCULAR AND CARDIAC DISEASES, TODAY REPORTED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2025, AND PROVIDED A BUSINESS UPDATE.

SOLID BIOSCIENCES REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES

CHARLESTOWN, MASS., MAY 01, 2025 (GLOBE NEWSWIRE) -- SOLID BIOSCIENCES INC.(NASDAQ: SLDB) (THE COMPANY), A LIFE SCIENCES COMPANY DEVELOPING PRECISION GENETIC MEDICINES FOR NEUROMUSCULAR AND CARDIAC DISEASES, TODAY ANNOUNCED GRANTS OF 81,000 RESTRICTED STOCK UNITS (RSUS) TO SEVEN NEWLY HIRED EMPLOYEES.

CHARLESTOWN, MASS., APRIL 30, 2025 (GLOBE NEWSWIRE) -- SOLID BIOSCIENCES INC. (NASDAQ: SLDB) (THE COMPANY OR SOLID), A LIFE SCIENCES COMPANY DEVELOPING PRECISION GENETIC MEDICINES FOR NEUROMUSCULAR AND CARDIAC DISEASES, ANNOUNCED THAT BO CUMBO, PRESIDENT AND CEO, WILL PARTICIPATE IN A FIRESIDE CHAT AT THE CITIZENS LIFE SCIENCES CONFERENCE ON WEDNESDAY, MAY 7, AT 12:30 PM ET.

SOLID BIOSCIENCES TO PARTICIPATE AT THE CITIZENS LIFE SCIENCES CONFERENCE

CHARLESTOWN, MASS., APRIL 29, 2025 (GLOBE NEWSWIRE) -- SOLID BIOSCIENCES INC. (NASDAQ: SLDB), A LIFE SCIENCES COMPANY DEVELOPING PRECISION GENETIC MEDICINES FOR NEUROMUSCULAR AND CARDIAC DISEASES, WILL PRESENT DATA FROM THE PHASE 1/2 INSPIRE DUCHENNE TRIAL EVALUATING SGT-003, A NEXT-GENERATION GENE THERAPY PRODUCT CANDIDATE INTENDED FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DUCHENNE), AT THE 28TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF GENE AND CELL THERAPY (ASGCT), FROM MAY 13-17, 2025, IN NEW ORLEANS, LA.

Solid Biosciences Inc.

SLDB

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Solid Biosciences Inc.

SLDB.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

SLDB